Abstract
Novartis’ generic drug unit Sandoz has agreed to acquire Fougera Pharmaceuticals, the former US dermatology business of Nycomed, for US$1.53 B in cash in order to become the leading player in the global generic dermatology market. Fougera reported sales of US$429 M in 2011, most of which came from the US, and Novartis aims to expand the company’s product sales globally. The acquisition will also provide the Swiss company with in-house expertise in topical dermatological products.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
